NeuroVasx, a medical device company which develops technologies for the minimally invasive treatment of hemorrhagic and ischemic stroke, has received the US Food & Drug Administration (FDA) approval for cPAX Aneurysm Treatment System to treat large, giant and wide-neck cerebral aneurysms.
cPAX, approved as a Humanitarian Use Device (HDE), is a polymeric strand delivered into the aneurysm using a technique similar to currently available platinum coil technologies.
cPAX, because of its soft polymeric material, is designed to achieve more complete filling of the aneurysm with the probable benefit of greater long term stability.
Compared to the current available technologies, cPAX offers physician to detach the device at any point versus a fixed detachment zone common in platinum coils.
Mayo Clinic in Jacksonville, Florida Neurosurgery associate professor and cPAX co-principal investigator Ricardo Hanel said the longer term stability seen in the clinical studies using cPAX in larger aneurysms gives great confidence in the positive impact this product will have on the care of patients.